The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate

Gonçalves, Sheila V. C. B.; Costa, Dorcas L.; Cantinho-Junior, João da J.; Vieira-Junior, José N.; Ishikawa, Edna A. Y.; Costa, Rubens N.; Costa-Filho, Antônio C. G.; Araújo, Ronald da C.; Uliana, Silvia R. B.; Yasunaka, Jenicer K. U. Y.; Coelho, Adriano C.; Costa, Jackson M. L.; Costa, Carlos H. N.

doi:10.3390/pathogens12070890

Cited by 1 publication

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, cutaneous leishmaniasis is the most common, and characterized by a wide range of clinical variations because of the involvement of the skin and mucous membranes of individuals (de Vries et al, 2015;Ornellas-Garcia et al, 2023). In this work, we used the species L. amazonensis, which is related to all types of clinical manifestations of leishmaniasis (Gatti et al, 2017;Gonçalves et al, 2023;Porto et al, 2022;Valdivia et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

4‐Quinolinylhydrazone analogues kill Leishmania (Leishmania) amazonensis by inducing apoptosis and mitochondria‐dependent pathway cell death

Granato,

Silva,

Lemos

et al. 2024

Chem Biol Drug Des

View full text Add to dashboard Cite

Despite efforts, available alternatives for the treatment of leishmaniasis are still scarce. In this work we tested a class of 15 quinolinylhydrazone analogues and presented data that support the use of the most active compound in cutaneous leishmaniasis caused by Leishmania amazonensis. In general, the compounds showed activity at low concentrations for both parasitic forms (5.33–37.04 μM to promastigotes, and 14.31–61.98 μM to amastigotes). In addition, the best compound (MHZ15) is highly selective for the parasite. Biochemical studies indicate that the treatment of promastigotes with MHZ15 leads the loss of mitochondrial potential and increase in ROS levels as the primary effects, which triggers accumulation of lipid droplets, loss of plasma membrane integrity and apoptosis hallmarks, including DNA fragmentation and phosphatidylserine exposure. These effects were similar in the intracellular form of the parasite. However, in this parasitic form there is no change in plasma membrane integrity in the observed treatment time, which can be attributed to metabolic differences and the resilience of the amastigote. Also, ultrastructural changes such as vacuolization suggesting autophagy were observed. The in vivo effectiveness of MHZ15 in the experimental model of cutaneous leishmaniasis was carried out in mice of the BALB/c strain infected with L. amazonensis. The treatment by intralesional route showed that MHZ15 acted with great efficiency with significantly reduction in the parasite load in the injured paws and draining lymph nodes, without clinical signs of distress or compromise of animal welfare. In vivo toxicity was also evaluated and null alterations in the levels of hepatic enzymes aspartate aminotransferase, and alanine aminotransferase was observed. The data presented herein demonstrates that MHZ15 exhibits a range of favorable characteristics conducive to the development of an antileishmanial agent.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In this work, we used the species L . amazonensis , which is related to all types of clinical manifestations of leishmaniasis (Gatti et al., 2017; Gonçalves et al., 2023; Porto et al., 2022; Valdivia et al., 2017).…”

Section: Introductionmentioning

confidence: 99%